Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
出版年份 2020 全文链接
标题
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-05-02
DOI
10.1002/ijc.33013
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety of nivolumab for metastatic biliary tract cancer
- (2019) Miaomiao Gou et al. OncoTargets and Therapy
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- (2019) Angela Lamarca et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
- (2019) Richard D. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes
- (2019) Maeve A. Lowery et al. CANCER
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- GenomicERBB2/ERBB3mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis
- (2018) Maolan Li et al. GUT
- Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma
- (2018) Richard Kim et al. Oncotarget
- 625PDPembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study
- (2018) M Ueno et al. ANNALS OF ONCOLOGY
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Biliary tract cancer: current challenges and future prospects
- (2018) Michele Ghidini et al. Cancer Management and Research
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials
- (2017) Manni Wang et al. Drug Design Development and Therapy
- PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
- (2017) Jacqueline Fontugne et al. Oncotarget
- Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue
- (2016) Marisa Dolled-Filhart et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started